PATENTS - Patented medicines - Excessive prices
Appeal by Alexion Pharmaceuticals from the dismissal of its application for judicial review of a decision of the Patented Medicine Prices Review Board finding that Alexion priced its drug, Soliris, excessively....To view the full article, register now.
Already a subscriber? Click here to view full article